Signatope offers next generation quantitative assays for your protein biomarker of interest.
SIGNATOPE’s mission is to support preclinical and clinical drug development by providing novel assays and assay services for drug-safety biomarkers in man and animals. A proprietary antibody-based enrichment coupled to highly sensitive mass spectrometry read-out (MS immunoassay) allows to quantify a wide variety of biomarkers in all pharmaceutically relevant species in one comparable format.
SIGNATOPE aims to become an established leader in protein analytical services for drug-induced organ injury biomarkers and drug-metabolizing enzymes.
Our team has been developing the core technology – Signabodies – at the NMI since 2008. By winning the GO-Bio-Grant worth 1,7 Mio. € in 2012 it was possible to develop cross-species assays panels for several drug induced organ toxicity biomarkers. In 2015 our business plan won a Science4Life award. In August 2016 we founded Signatope GmbH. Two months later High-Tech-Gruenderfond invested in the company. In 2017 we were able to obtain the GO-Bio phase 2 grant for the qualification of a broader set of safety biomarkers required for pharmaceutical research.